Startup Deep Dive : HealthPlix — the doctor EMR firm that cut its losses by two-thirds after laying off a quarter of its staff

HealthPlix signed more than 10,000 doctors onto its electronic medical record software, and yet in the year to March 2024 it lost roughly ₹1.66 for every ₹1 it collected: a net loss of ₹51.4 crore (about $53.5 million at $1 ≈ ₹96.0) on operating revenue of ₹30.9 crore, as per figures compiled by Inc42 from the company’s Registrar of Companies filings. That is the paradox of building software for Indian doctors. The product works, the doctors use it, and the maths still refuses to add up.

Then something changed. In FY25 HealthPlix cut its net loss to ₹19.0 crore on revenue of ₹38.4 crore, per Inc42’s reading of the FY25 filing, after laying off about a quarter of its staff in April 2024, as first reported by Inc42. This is the story of a Bengaluru startup that built one of India’s most widely used doctor-facing EMR platforms, spent nine years and more than $40 million learning that adoption is not the same as profit, and only started closing the gap once it stopped hiring and started subtracting.

Quick facts

What HealthPlix does

HealthPlix sells software to individual doctors and clinics, not to patients. Its core product is an assistive, AI-supported electronic medical record (EMR) system that lets a doctor generate a digital prescription in about 30 seconds, in as many as 20 languages, while the software offers clinical decision support at the point of care, as described by co-founder Sandeep Gudibanda in a YourStory interview from October 2021. Bundled around the prescription are appointment scheduling, patient history, billing, and online-consultation tools. In short, it is a workflow layer that sits between the doctor and the patient record, aimed at replacing the paper prescription pad with something that captures structured data.

The origin: a dialysis founder’s insight

The founding insight came from watching things go wrong. Before HealthPlix, Sandeep Gudibanda had co-founded NephroPlus, a chain of dialysis centres in India, where he saw at close range how many patients arrived in kidney failure that better-managed diabetes and hypertension might have prevented, as recounted in YourStory’s coverage of the company. That observation, that a large share of chronic-disease patients deteriorate because of avoidable gaps in day-to-day clinical management rather than because medicine lacks the answers, became the reason to build a decision-support tool that lives inside the doctor’s own workflow.

HealthPlix Technologies was incorporated on 21 October 2014 in Bengaluru, per its Ministry of Corporate Affairs record, by Gudibanda together with Raghuraj Sunder Raju, who had earlier worked at Nokia and Huawei, and Prasad Basavaraj, its chief technology officer. The bet was deliberately broad from the start: a platform that was disease-agnostic and geography-agnostic, meant to give any doctor real-time support rather than to specialise in one condition. That ambition explains both the eventual scale of the doctor network and the difficulty of charging enough to cover its cost.

The struggle years

HealthPlix grew its user base far faster than its revenue, and the gap showed up first as widening losses and later as job cuts. Two episodes stand out.

The first was structural and ran for years: employee costs consistently dwarfed sales. In FY23 employee-benefit expenditure was ₹53.9 crore, about 75% of total expenses of ₹71.5 crore, and up 65% from ₹32.6 crore in FY22, as reported by TheKredible from the company’s filings. Against that cost base, operating revenue in FY23 was ₹29.1 crore. A software business that pays out nearly two rupees in salary for every rupee of revenue is spending to acquire and support doctors faster than those doctors pay it back. The net loss widened accordingly, from ₹35.8 crore in FY22 to ₹41.9 crore in FY23 and then ₹51.4 crore in FY24, per TheKredible and Inc42.

The second episode was the reckoning. In April 2024 HealthPlix cut about 100 employees, roughly a quarter of its workforce, as first reported by Inc42. The company attributed most of the exits to performance issues surfaced during annual appraisals, concentrated in the sales division, with the remainder from role redundancies; it said departing staff received severance, in most cases about two months’ pay. Management framed the restructuring as aligning the company with its next phase of growth and an eventual push toward enterprise and international customers. Stripped of the framing, it was a business that had hired ahead of its revenue and had to reverse.

The turning point

The single event that changed HealthPlix’s financial shape was that FY25 restructuring, and the numbers on each side of it are stark. Going in, FY24 closed with a net loss of ₹51.4 crore on revenue of ₹30.9 crore and total expenses of ₹82.3 crore, per Inc42’s reading of the RoC filing. Coming out, FY25 revenue rose to ₹38.4 crore while total expenses fell to ₹57.4 crore, and the net loss shrank to ₹19.0 crore, per Inc42. That is a roughly ₹25 crore fall in the cost base in a single year and a net loss cut by about two-thirds, achieved mostly by removing headcount rather than by any sudden surge in sales. Revenue grew a respectable 24.3% year on year, but the swing in the loss was overwhelmingly a cost story. For a company that had lost money at an accelerating rate for three straight years, FY25 was the first year the direction of travel reversed.

The money behind it

HealthPlix has raised roughly $43 million to $45 million across its life, per Tracxn and Inc42, from a familiar set of Indian venture names rather than from Sequoia/Peak XV, which does not appear in its cap table on the sources reviewed here. The rounds, in order:

• Series A, July 2018: $3 million (about ₹29 crore), led by IDG Ventures India (now Chiratae Ventures) and Kalaari Capital, per Entrackr. At the time the company had 42 employees and a presence in about 150 cities.
• Series B, June 2020: $6 million led by JSW Ventures, with Kalaari and Chiratae participating, per Business Standard.
• Series B extension, March 2021: $13.5 million (about ₹130 crore) led by Lightspeed Venture Partners, with JSW Ventures, Kalaari and Chiratae, per YourStory and Entrepreneur India.
• Series C, 15 March 2023: $22 million (about ₹211 crore) led by Avataar Venture Partners and SIG Venture Capital, with existing backers Lightspeed, JSW Ventures, Kalaari and Chiratae, per Entrackr and YourStory. It remains the company’s most recent primary equity round on the record.
• Debt/venture-debt participation over the years has included lenders such as BlackSoil Capital and InnoVen Capital, per investor aggregators.

What each backer changed is visible in the trajectory: Kalaari and IDG/Chiratae provided the early institutional capital that took HealthPlix from a 42-person team to a multi-city network; Lightspeed’s 2021 round funded an aggressive expansion in doctors and specialties; and the Avataar and SIG-led Series C in 2023 was pitched as fuel for product and technology and for scaling user acquisition. On valuation, HealthPlix has not officially disclosed a figure; secondary trackers such as PitchBook have listed a number in the region of $60 million as of 2022, which should be treated as unconfirmed aggregator data rather than a company-stated mark.

How it makes money

The business model is subscription software sold to doctors. The parts worth spelling out:

• Money in: doctors and clinics pay recurring subscription fees to use the EMR and productivity suite. Revenue is therefore a function of how many doctors are on the platform and how much each pays per year, not of patient volumes or per-consultation charges.
• Costs out: the dominant cost is people. Employee-benefit expense was about 75% of total expenses in FY23 (₹53.9 crore of ₹71.5 crore), per TheKredible, split between a large field-sales force to sign up doctors and the engineering and support teams to build and service the product.
• Where the margin sits: gross economics on software are attractive per doctor once acquired, but the sales cost to acquire each doctor and the modest ticket size per subscription meant that, through FY24, the company spent more to grow than it earned back.
• The part people get wrong: HealthPlix is not a patient-facing consumer app competing with teleconsultation marketplaces. It monetises the doctor’s workflow. Its unit of value is a paying physician, which is a slower, stickier, lower-churn customer than a consumer but also a harder one to charge a large annual fee.

The numbers

Four years of the profit-and-loss account, in ₹ crore, as compiled by TheKredible and Inc42 from HealthPlix’s RoC filings (operating revenue and net loss):

Read top to bottom, the pattern is clear: revenue roughly doubled from FY22 to FY23, then grew more slowly (about 6% in FY24, then about 24% in FY25), while losses climbed for three years before the FY25 cost cut. Total assets stood at about ₹87.4 crore at the end of FY25, per Inc42, and the company reported a headcount of about 283 in FY25, down from the roughly 400 it had before the April 2024 layoffs.

Where the money comes from

HealthPlix’s reach is concentrated in a way that surprises people who assume health-tech is a metro phenomenon:

• Doctor base: more than 10,000 doctors were on the platform at the March 2023 Series C, per Entrackr; the company more recently describes over 12,000 doctors, a company-stated figure that should be read as such.
• Geography: the network spans more than 370 cities, and the company states that about 70% of its doctors practise outside metro cities, a distribution that points to smaller-town clinics rather than large urban hospitals as the core customer.
• Specialties and scale: HealthPlix says its software is used across 16 medical specialties and that doctors on the platform have treated more than 30 million patients cumulatively, both company-stated figures.
• Revenue mix: the company earns almost entirely from doctor subscriptions in India; management has spoken of building enterprise and international offerings, but as of the latest filings the reported revenue is domestic software subscription income.

The surprise, then, is that the growth engine is non-metro India. That is a large, underserved market for digitisation, but it is also a price-sensitive one, which feeds directly into the company’s central tension between scale and pricing power.

The risks

• Cost structure and cash burn: even after the FY25 improvement, the company still lost ₹19.0 crore on ₹38.4 crore of revenue, per Inc42, and its last primary equity round was in March 2023. If losses do not keep narrowing, it will need either fresh capital on terms set by a tougher 2025-26 market or further cost cuts, both of which constrain growth.
• Monetisation versus adoption: the FY23 filing showed employee costs at about 75% of expenses against revenue barely a third of that, per TheKredible. The mechanism of the risk is simple: signing more price-sensitive, non-metro doctors adds sales and support cost immediately while the incremental subscription revenue per doctor is small, so scale can deepen losses rather than cure them unless average revenue per doctor rises.
• Competition and switching: the EMR and clinic-software market in India includes larger and better-funded players in adjacent categories, and doctors can and do revert to paper or free tools. Because value depends on daily use, any dip in engagement threatens renewals directly.
• Regulatory and data risk: HealthPlix handles sensitive patient health data at scale, which brings it within the ambit of India’s Digital Personal Data Protection Act and evolving health-data rules; compliance cost and any breach would fall on a company that is not yet profitable.

The takeaway

The transferable lesson from HealthPlix is that in vertical SaaS, distribution is not the same as a business. HealthPlix solved the hard part that most health-tech founders never reach: it got tens of thousands of doctors to actually use its software every day, in hundreds of cities, mostly outside the metros. That is a genuine moat. But daily usage financed by venture capital is a cost centre until the average customer pays more than they cost to serve, and for HealthPlix that day was still not fully arrived even in FY25. The company’s own filings tell the story more honestly than any pitch: three years of widening losses, one hard round of layoffs, and then, for the first time, a loss that shrank. Growth got HealthPlix into the market. Only subtraction started to make it a company.

Frequently asked questions

What does HealthPlix do?

HealthPlix makes subscription software for doctors, centred on an AI-supported electronic medical record (EMR) that generates digital prescriptions in about 30 seconds and bundles appointments, patient records, billing and teleconsultation. It sells to doctors and clinics, not to patients, per the company and YourStory’s 2021 interview with its CEO.

How much money does HealthPlix make and is it profitable?

No, it was not profitable as of its latest filing. HealthPlix reported revenue of ₹38.4 crore and a net loss of ₹19.0 crore in FY25 (year to March 2025), an improvement on the ₹51.4 crore loss on ₹30.9 crore of revenue in FY24, per Inc42’s reading of its RoC filings.

Who founded HealthPlix and when?

HealthPlix Technologies was incorporated in Bengaluru on 21 October 2014, per its MCA record, by Sandeep Gudibanda (CEO), Raghuraj Sunder Raju (managing director) and Prasad Basavaraj (CTO). Gudibanda had earlier co-founded the dialysis chain NephroPlus.

Who are HealthPlix’s investors and how much has it raised?

HealthPlix has raised roughly $43 million to $45 million, per Tracxn and Inc42, from Lightspeed Venture Partners, Avataar Venture Partners, SIG Venture Capital, JSW Ventures, Kalaari Capital and Chiratae Ventures (formerly IDG Ventures India). Its largest round was a $22 million Series C in March 2023, per Entrackr.

Why did HealthPlix lay off staff in 2024?

In April 2024 HealthPlix cut about 100 employees, roughly 25% of its workforce, citing performance issues found during appraisals, largely in sales, plus role redundancies, as first reported by Inc42. The cut coincided with a sharp fall in total expenses and a narrower loss in FY25.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Inc42, HealthPlix financials (FY24 and FY25 revenue, losses, expenses, assets, headcount), accessed September 2026.
• Inc42, “HealthPlix Axes 25% Workforce Due To Performance Issues, Role Redundancies,” April 2024.
• TheKredible, “Healthplix records 2X rise in topline in FY23, losses widen” (FY22 and FY23 revenue, losses, employee costs), 2023.
• Entrackr, “HealthPlix raises $22 Mn in Series C round,” March 2023.
• Entrackr, “IDG and Kalaari lead $3 Mn Series A round in healthtech startup HealthPlix,” July 2018.
• YourStory, “HealthPlix Technologies raises $22M in Series C funding,” March 2023; and TechSparks 2021 interview with Sandeep Gudibanda, October 2021.
• Business Standard, “HealthPlix raises $6 million through Series-B funding led by JSW Ventures,” June 2020.
• Entrepreneur India / YourStory, HealthPlix $13.5 million Series B led by Lightspeed, March 2021.
• Tracxn, HealthPlix company, founders and funding profile, accessed September 2026.
• Ministry of Corporate Affairs / ZaubaCorp, HealthPlix Technologies Private Limited (CIN U72200KA2014PTC076858), incorporation date, accessed September 2026.
• PitchBook, HealthPlix company profile (valuation estimate, unconfirmed), accessed September 2026.

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.